
Bioactivity profiles for uncharacterised compounds


Computational Applications in Secondary Metabolites Discovery (CAiSMD), March 9 (2021)

Miquel Duran-Frigola, PhD

@mduranfrigola


miquel@ersilia.io

ersilia.io



The Chemical Checker, Ersilia's backbone technology

Structural Bioinformatics and Network Biology lab





Structural
Bioinformatics &
Network Biology
Dr. Patrick Aloy

– Prof. Patrick Aloy
– Dr. Eduardo Pauls
– Dr. Martino Bertoni



– Pau Badia-i-Mompel
– Oriol Guitart
– Víctor Alcalde

Structural Bioinformatics and **Network Biology** lab



Duran-Frigola et al. WIREs Advanced Reviews, 2019
 Fernandez-Torras et al, in preparation

Classical chemical fingerprints



Chemical Checker signature

Halofantrine belongs to the class of organic compounds known as **phenanthrenes** and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene. Halofantrine is a synthetic **antimalarial** which acts as a **blood schizonticide**. It is effective against multi drug resistant (including mefloquine resistant) *P. falciparum* malaria. The mechanism of action of Halofantrine may be similar to that of chloroquine, quinine, and mefloquine; by forming toxic **complexes with ferritoporphyrin IX** that damage the membrane of the parasite. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme '**heme polymerase**'), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated **HERG channels** leading to some degree of **cardiotoxicity**. Side effects include coughing noisy, rattling, troubled breathing, loss of appetite, aches and pain in joints, indigestion, and **skin itching** or rash, *et cetera, et cetera*.




The bioactive chemical space, organised

| | | | | | |
|-----------|---------------------|---------------------|--------------------|-------------------------|------------------------|
| Chemistry | 2D fingerprints | 3D fingerprints | Scaffolds | Structural keys | Physico-chemistry |
| Targets | Mechanism of action | Metabolic genes | Crystals | Binding | HTS bioassays |
| Networks | Small mol. roles | Small mol. pathways | Signaling pathways | Biological processes | Interactome |
| Cells | Gene expression | Cancer cell lines | Chemical genetics | Morphology | Cell bioassays |
| Clinics | Therapeutic areas | Indications | Side effects | Diseases and toxicology | Drug-drug interactions |


- 800k bioactive molecules
- 25 data types, from chemistry to the clinics
- The major small molecule databases are integrated
- Inference by deep learning
- chemicalchecker.org
- bioactivitysignatures.org



Duran-Frigola et al. Nat Biotech, 2020
 Bertoni*, Duran-Frigola* et al. BioRxiv, 2020
 🏆 CTD2-pancancer DREAM challenge, 2020



A tiny chunk of the database




Classical solution

Chemical Checker solution

Beyond chemical similarity

10k compounds



Chemically similar


Chemically diverse




Stacked CC signature

Complex similarity searches




Transcriptional response




Cell sensitivity profiles




Chemical structure




Chlorambucil



Mitomycin






Teniposide



New molecule

Complex similarity searches



Antibiotics


A web-based interface

Chemical Checker
chemicalchecker.org

Imatinib
 APD EXD
 MET TCM...

Mol. Weight: 493.62 g/mol
 Ro5 Violations: 0
 Chemical Beauty: 0.372

Popularity: 0.791
 Singularity: 0.326
 Targets: ABL, CSF1R, DDR1...



1 2 3 4 5

A B C D E

| Row | 1 | 2 | 3 | 4 | 5 |
|-----|---------|---------|---------|---------|---------|
| A | Similar | Similar | Similar | Similar | Similar |
| B | Similar | Similar | Similar | Similar | Similar |
| C | Similar | Similar | Similar | Similar | Similar |
| D | Similar | Similar | Similar | Similar | Similar |
| E | Similar | Similar | Similar | Similar | Similar |

● Similar
 ○ Inferred similar
 • Not similar

1 2 3 4 5

Browser tab
 Query molecule
 Zoom in on 2D proj.
 Explore other mols.
 Similar molecules
 Download

Nilotinib
 Ponatinib
 Sorafenib
 Dasatinib
 Bosutinib
Masitinib
 Schembl13637790
 Gefitinib
 Schembl12569230
 Us8703771, 12
 Schembl12574112
 Us8703771, 13
 Schembl12573360
 Erlotinib
 Chembl13642833
 Chembl13690083
 Chembl13690080

10^{60} possible molecules...*

200M are commercially available...*




100k molecules...*
10k commercially available...*
1% of them have binding data
10k compounds have public cell-based 'omics' data
5k compounds are approved / experimental drugs
Half of the drugs are inspired by natural products*

An honest view of the Chemical Checker

| | Chemistry | | | | |
|----------|---------------------|---------------------|--------------------|-------------------------|------------------------|
| | 2D fingerprints | 3D fingerprints | Scaffolds | Structural keys | Physico-chemistry |
| Targets | Mechanism of action | Metabolic genes | Crystals | Binding | HTS bioassays |
| Networks | Small mol. roles | Small mol. pathways | Signaling pathways | Biological processes | Interactome |
| Cells | Gene expression | Cancer cell lines | Chemical genetics | Morphology | Cell bioassays |
| Clinics | Therapeutic areas | Indications | Side effects | Diseases and toxicology | Drug-drug interactions |

– Siamese neural nets 🧐



– bioactivitysignatures.org


– `pip install signaturizer`

High-performance computing




Large-scale inference of bioactivity signatures



Prediction



(a) Accuracy




(b) Confidence




- | | | | | |
|--------------------------|-----------------------------|------------------------|---------------------------|----------------------------|
| A1: 2D fingerprints | A2: 3D fingerprints | A3: Scaffolds | A4: Structural keys | A5: Physicochemistry |
| B1: Mechanisms of action | B2: Metabolic genes | B3: Crystals | B4: Binding | B5: HTS bioassays |
| C1: Small molecule roles | C2: Small molecule pathways | C3: Signaling pathways | C4: Biological processes | C5: Interactome |
| D1: Transcription | D2: Cancer cell lines | D3: Chemical genetics | D4: Morphology | D5: Cell bioassays |
| E1: Therapeutic areas | E2: Indications | E3: Side effects | E4: Diseases & toxicology | E5: Drug-drug interactions |

High ●
 Medium ●
 Low ●


– Drug molecules




– Species metabolites



– Tissues and fluids



– Food ingredients




Take-home messages

- The CC contains compound signatures of **25** different types
- **Experimental** signatures are *not* always available for the compounds
- **Inferred** signatures are available for *every* compound (with a confidence estimate)
- CC signatures can be used to **match** and **revert** perturbational and disease signatures*
- 2D projections help **visualise** compound collections
- CC signatures can be used as drop-in **replacements** for chemical fingerprints (e.g. similarity search, SAR modelling)

* Not shown today

Thanks for your attention!



Bioactivity profiles for uncharacterised compounds

Computational Applications in Secondary Metabolites Discovery (CAiSMD), March 9 (2021)

Miquel Duran-Frigola, PhD

@mduranfrigola

miquel@ersilia.io

ersilia.io